CA19-9 Antibody (DA122)

Description

Carbohydrate Antigen 19-9 (CA19-9) is a sialylated Lewis A blood group antigen.1 It is synthesized by glycosyltransferases and has been identified as a component of gangliosides, glycoproteins and mucins.1,2 Anti-CA19-9 reacts with epithelial cells of normal pancreas, stomach, and colon as well as various adenocarcinomas, including pancreatic, gastric, and colorectal adenocarcinomas.3,4 — Références — 1. Wu E, et al. CA 19-9 and Pancreatic Cancer. Clin Adv Hematol Oncol. 2013; 11:53-5. 2. Partyka K, et al. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics. 2012; 12:2212-20. 3. Remmers N, et al. Aberrant expression of mucin core proteins and O-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res. 2013; 19:1981-93. 4. Terada T. An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: III expressions of EMA, CEA, CA19-9, CDX-2, p53, Ki-67 antigen, TTF-1, vimentin, and p63 in normal mucosa and in 42 cases. Int J Clin Exp Pathol. 2013; 6:630-8.

Caractéristiques

Type

Recombinant monoclonal mouse antibody

Clone

DA122

Isotype

Mouse

Réactivité

Synthetic peptide of human CA 19-9

Localisation

Cytoplasm

Usage prévu

IHC (FFPE)